QQ客服 官方微博 反馈留言

	A preclinical evaluation of SKLB261, a multi-kinase inhibitor of EGFR/Src/VEGFR2, as a therapeutic agent against pancreatic cancer.
	Pan Y; Zheng M; Zhong L; Yang J; Zhou S; Qin Y; Xiang R; Chen Y; Yang SY.
刊名	Molecular Cancer Therapeutics
	2015
卷号	Vol.14 No.2页码:407-418
ISSN号	1535-7163
URL标识	查看原文
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/1908241
专题	四川大学
作者单位	1.Department of Clinical Medicine, Nankai University. 2.State Key Laboratory of Biotherapy and Cancer Center/Collaborative Innovation Center of Biotherapy, Sichuan University yangsy@scu.edu.cn. 3.State Key Laboratory of Biotherapy and Cancer Center/Collaborative Innovation Center of Biotherapy, Sichuan University. 4.Department of Pharmacy, National University of Singapore.
推荐引用方式 GB/T 7714	Pan Y,Zheng M,Zhong L,et al. A preclinical evaluation of SKLB261, a multi-kinase inhibitor of EGFR/Src/VEGFR2, as a therapeutic agent against pancreatic cancer.[J]. Molecular Cancer Therapeutics,2015,Vol.14 No.2:407-418.
APA	Pan Y.,Zheng M.,Zhong L.,Yang J.,Zhou S.,...&Yang SY..(2015).A preclinical evaluation of SKLB261, a multi-kinase inhibitor of EGFR/Src/VEGFR2, as a therapeutic agent against pancreatic cancer..Molecular Cancer Therapeutics,Vol.14 No.2,407-418.
MLA	Pan Y,et al."A preclinical evaluation of SKLB261, a multi-kinase inhibitor of EGFR/Src/VEGFR2, as a therapeutic agent against pancreatic cancer.".Molecular Cancer Therapeutics Vol.14 No.2(2015):407-418.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。